Splenic Marginal Zone Lymphoma (DBCOND0028622)

Identifiers

Synonyms

Splenic marginal zone lymphomas / Splenic marginal zone lymphoma / Small cell B-cell lymphoma / Marginal zone lymphoma of spleen (disorder) / Splenic marginal zone B-cell lymphoma (disorder) / Splenic marginal zone lymphoma NOS / Splenic marginal zone B-cell lymphoma (morphologic abnormality) / Splenic lymphoma with villous lymphocytes (disorder)

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT05544019	Study of SGR-1505 in Mature B-Cell Neoplasms	No drug interventions	treatment	1	recruiting
NCT05735834	Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients	Rituximab Zanubrutinib	treatment	3	recruiting
NCT01233921	Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer	Palifermin	supportive_care	Not Available	completed
NCT01748721	MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma	Ontuxizumab	treatment	1	completed
NCT00082784	Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms	Alvocidib Bortezomib	treatment	1	completed
NCT01116154	Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma	Lenalidomide Vorinostat	treatment	1	terminated
NCT00006251	Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	1 / 2	completed
NCT00293345	3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma	Gemcitabine Triapine	treatment	1	completed
NCT01258998	Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma	No drug interventions	treatment	2	completed
NCT00054483	Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction	Bortezomib Bortezomib D-mannitol	basic_science	1	completed
NCT00608361	Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery	Dasatinib	treatment	1	completed
NCT01045928	Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma	Lenalidomide Rituximab	treatment	1	terminated
NCT01177371	High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma	Busulfan Cyclophosphamide Cyclosporine Methotrexate Methylprednisolone Methylprednisolone hemisuccinate	treatment	2	completed
NCT00110071	Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma	Fludarabine	treatment	1	completed
NCT01558778	Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant	No drug interventions	supportive_care	Not Available	withdrawn
NCT01254578	Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers	Lenalidomide	treatment	1	completed
NCT00082888	Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma	Tipifarnib	treatment	2	completed
NCT01567709	Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma	Alisertib Vorinostat	treatment	1	completed
NCT00354185	PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma	Belinostat Tanespimycin	treatment	1	terminated
NCT01484015	Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia	Cefepime	treatment	1	completed
NCT00068315	Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia	Bortezomib Bortezomib D-mannitol Fludarabine Rituximab	treatment	1	completed
NCT00025415	Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction	Imatinib	treatment	1	completed
NCT01805037	Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas	Brentuximab vedotin Rituximab	treatment	1 / 2	terminated
NCT00566332	Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia	Chlorambucil Fludarabine	treatment	3	completed
NCT00118352	Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer	Alemtuzumab Cyclosporine Fludarabine Mycophenolate mofetil	treatment	2	completed
NCT01239875	Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma	Streptococcus pneumoniae type 1 capsular polysaccharide antigen Streptococcus pneumoniae type 10a capsular polysaccharide antigen Streptococcus pneumoniae type 11a capsular polysaccharide antigen Streptococcus pneumoniae type 12f capsular polysaccharide antigen Streptococcus pneumoniae type 14 capsular polysaccharide antigen Streptococcus pneumoniae type 15b capsular polysaccharide antigen Streptococcus pneumoniae type 17f capsular polysaccharide antigen Streptococcus pneumoniae type 18c capsular polysaccharide antigen Streptococcus pneumoniae type 19a capsular polysaccharide antigen Streptococcus pneumoniae type 19f capsular polysaccharide antigen Streptococcus pneumoniae type 2 capsular polysaccharide antigen Streptococcus pneumoniae type 20 capsular polysaccharide antigen Streptococcus pneumoniae type 22f capsular polysaccharide antigen Streptococcus pneumoniae type 23f capsular polysaccharide antigen Streptococcus pneumoniae type 3 capsular polysaccharide antigen Streptococcus pneumoniae type 33f capsular polysaccharide antigen Streptococcus pneumoniae type 4 capsular polysaccharide antigen Streptococcus pneumoniae type 5 capsular polysaccharide antigen Streptococcus pneumoniae type 6b capsular polysaccharide antigen Streptococcus pneumoniae type 7f capsular polysaccharide antigen Streptococcus pneumoniae type 8 capsular polysaccharide antigen Streptococcus pneumoniae type 9n capsular polysaccharide antigen Streptococcus pneumoniae type 9v capsular polysaccharide antigen	treatment	0	completed
NCT00003970	Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma	Irinotecan	treatment	1	completed
NCT01479842	Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma	Bendamustine Ibrutinib Rituximab Tyrosine	treatment	1	active_not_recruiting
NCT00005799	Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer	Cyclosporine Fludarabine Mycophenolate mofetil Therapeutic allogeneic lymphocytes	treatment	Not Available	completed
NCT01815749	Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma	No drug interventions	treatment	1	active_not_recruiting
NCT02213913	Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas	Cyclophosphamide Doxorubicin Etoposide Lenalidomide Prednisone Rituximab Sulfate ion Vincristine	treatment	1 / 2	active_not_recruiting
NCT01384513	A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies	Busulfan Cyclophosphamide Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT00073918	Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	Cyclophosphamide Etoposide	treatment	2	completed
NCT02049541	Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma	Buparlisib Rituximab	treatment	1	completed
NCT01839916	Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Therapeutic allogeneic lymphocytes	treatment	2	completed
NCT00078858	Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	1 / 2	completed
NCT01720758	Assessment of the V600E Mutation in the B-RAF Gene in Chronic Lymphoproliferative Disease	No drug interventions	Not Available	Not Available	completed
NCT00014235	Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	Not Available	completed
NCT01093586	Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Antilymphocyte immunoglobulin (horse) Antithymocyte immunoglobulin (rabbit) Busulfan Cyclophosphamide Cyclosporine Methylprednisolone Methylprednisolone hemisuccinate Mycophenolate mofetil	treatment	2	completed
NCT01158274	RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors	Capecitabine RG-4733	treatment	1	completed
NCT00026182	Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma	Edodekin alfa Natural Killer Cell Rituximab	treatment	2	completed
NCT01529827	Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Fludarabine Melphalan Methotrexate Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT00058227	Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma	Alvocidib Fludarabine Rituximab	treatment	1	completed
NCT00089076	MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma	Ipilimumab	treatment	1 / 2	terminated
NCT00098891	MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas	Entinostat Isotretinoin	treatment	1	completed
NCT01199562	Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant	Foscarnet Ganciclovir Valganciclovir	Not Available	Not Available	completed
NCT00010192	Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer	Aldesleukin Rituximab	treatment	1	completed
NCT00101244	SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma	Ispinesib	treatment	1	terminated
NCT01682044	Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma	Filgrastim Pegfilgrastim Rituximab	treatment	2	completed
NCT01159067	Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload	Deferasirox	supportive_care	2	terminated
NCT00049504	Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer	Cyclophosphamide Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT00891072	Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	Carboplatin Isosorbide Paclitaxel	treatment	1	completed
NCT02254772	A Phase I/II Study of Intratumoral Injection of SD-101	Ipilimumab Toll-like receptor 9	treatment	1 / 2	completed
NCT00040846	Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies	Alemtuzumab Cyclosporine Fludarabine Mycophenolate mofetil	treatment	2	completed
NCT00060112	Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma	Gemcitabine	treatment	1	terminated
NCT03697512	MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas	Ibrutinib Rituximab	treatment	2	active_not_recruiting
NCT00003210	Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease	Edodekin alfa Natural Killer Cell	treatment	2	completed
NCT00088881	Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma	Cyclophosphamide Doxorubicin Prednisone Rituximab Sulfate ion Vincristine	treatment	2	terminated
NCT00408681	Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant	Lithium carbonate	supportive_care	Not Available	completed
NCT00005950	506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma	Nelarabine	treatment	2	terminated
NCT01523223	Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies	Therapeutic allogeneic lymphocytes	treatment	1	completed
NCT00019708	Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma	Tanespimycin	treatment	1	terminated
NCT01678443	Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies	Indium Yttrium Y-90	treatment	1	terminated
NCT01408043	Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma	Etoposide Filgrastim Plerixafor	treatment	Not Available	terminated
NCT01075321	Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma	Everolimus Lenalidomide	treatment	1 / 2	completed
NCT01326702	Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors	Bendamustine Rituximab Veliparib	treatment	1 / 2	completed
NCT02281279	Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma	Lenalidomide Rituximab Romidepsin	treatment	1 / 2	withdrawn
NCT00918333	Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma	Everolimus Panobinostat	treatment	1 / 2	completed
NCT01959477	Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant	Busulfan Cyclophosphamide Etoposide	treatment	0	completed
NCT01261247	Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma	Panobinostat	treatment	2	completed
NCT01044745	Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer	Antilymphocyte immunoglobulin (horse) Antithymocyte immunoglobulin (rabbit) Busulfan Cyclophosphamide Fludarabine Mycophenolate mofetil Rituximab Tacrolimus	treatment	2	terminated
NCT00012298	Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	Filgrastim Ibritumomab tiuxetan Oprelvekin Rituximab	treatment	1 / 2	terminated
NCT00343798	A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies	Cyclophosphamide Cyclosporine Fludarabine Mycophenolate mofetil	treatment	1	completed
NCT00058305	Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin's Lymphoma After Bone Marrow or Stem Cell Transplantation	Bryostatin 1 Sulfate ion Vincristine	treatment	2	completed
NCT01812005	Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma	Alisertib Rituximab	treatment	2	terminated
NCT00799461	Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications	No drug interventions	supportive_care	3	completed
NCT00711828	Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma	Bortezomib Cyclophosphamide Dexamethasone Rituximab	treatment	2	completed
NCT01769911	Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma	6-O-benzylguanine Carmustine Cytarabine Etoposide Melphalan	treatment	Not Available	withdrawn
NCT00089011	Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer	Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT00499811	Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction	Vorinostat	treatment	1	completed
NCT00112593	Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	Not Available	completed
NCT00089271	17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas	Alvespimycin	treatment	1	completed
NCT00856388	Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders	Antilymphocyte immunoglobulin (horse) Antithymocyte immunoglobulin (rabbit) Fludarabine Melphalan	treatment	Not Available	completed
NCT00769288	FAU in Treating Patients With Advanced Solid Tumors or Lymphoma	No drug interventions	treatment	1	completed
NCT02168907	CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma	Bendamustine Devimistat Lipoic acid Rituximab	treatment	1	terminated
NCT02037256	Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma	Bortezomib Bortezomib D-mannitol Filgrastim	treatment	Not Available	completed
NCT00348985	PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas	Belinostat Bortezomib Bortezomib D-mannitol	treatment	1	completed
NCT02652715	Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma	No drug interventions	basic_science	Not Available	completed
NCT01701232	Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's Lymphoma	Rituximab	treatment	3	completed
NCT00621452	Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma	Aldesleukin Cyclophosphamide	treatment	1	completed
NCT01076270	Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Filgrastim Plerixafor	treatment	Not Available	terminated
NCT00118170	Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function	Sorafenib	treatment	1	completed
NCT00601718	Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma	Carboplatin Etoposide Ifosfamide Rituximab Vorinostat	treatment	1 / 2	completed
NCT02945319	Integrated Molecular and Clinical Profiling to Optimize Outcome Prediction in Splenic Marginal Zone Lymphoma	No drug interventions	Not Available	Not Available	completed
NCT01231919	MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia	No drug interventions	treatment	1	completed
NCT01658319	Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies	Fludarabine Methoxyamine	treatment	1	completed
NCT00004241	17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma	Tanespimycin	treatment	1	completed
NCT02109224	Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection	Ibrutinib	treatment	1	terminated
NCT00003196	Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma	Cyclosporine Mycophenolate mofetil Therapeutic allogeneic lymphocytes	treatment	Not Available	completed
NCT00720135	Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma	Rituximab	treatment	1	completed
NCT01110135	Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma	Bendamustine Dexamethasone Etoposide Filgrastim	treatment	2	completed
NCT00005786	Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia	Arsenic trioxide Arsenous acid	treatment	Not Available	terminated
NCT00054639	Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma	Rituximab	treatment	2	completed
NCT01769222	Ipilimumab and Local Radiation for Selected Solid Tumors	Ipilimumab	treatment	1	terminated
NCT01273766	Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies	Deferasirox	supportive_care	2	completed
NCT04223765	Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.	Bendamustine Cyclophosphamide Fludarabine	treatment	1	recruiting
NCT00458731	Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma	Bevacizumab Cediranib	treatment	1	completed
NCT00275080	Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia	2'-Deoxycytidine Decitabine Vorinostat	treatment	1	completed
NCT00438880	Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma	Agatolimod Rituximab	treatment	1 / 2	completed
NCT00867529	Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma	Rituximab	treatment	2	completed
NCT00119392	Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	Cyclosporine Fludarabine Mycophenolate mofetil Rituximab	treatment	2	completed
NCT00288067	Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma	Fenretinide Rituximab	treatment	1 / 2	terminated
NCT00536601	High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors	Busulfan Carboplatin Carmustine Cyclophosphamide Etoposide Melphalan Thiotepa	treatment	Not Available	completed
NCT00290472	CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia	Menthol Temsirolimus	treatment	2	completed
NCT00103272	17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer	Bortezomib Bortezomib D-mannitol Tanespimycin	treatment	1	terminated
NCT00017472	Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid Leukemia	Apolizumab	treatment	1	completed
NCT00795769	Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant	Ondansetron	supportive_care	2	completed
NCT01238146	Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma	Bendamustine Obatoclax Rituximab	treatment	1 / 2	withdrawn
NCT01427881	Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies	Busulfan Cyclophosphamide Cyclosporine Fludarabine	treatment	2	completed
NCT01419795	Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant	Lenalidomide Rituximab	treatment	2	terminated
NCT00072514	Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies	Carboplatin Dexamethasone Gemcitabine Rituximab	treatment	2	completed
NCT01652014	Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies	Cyclophosphamide Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	withdrawn
NCT00244855	Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma	Dexamethasone Rituximab	treatment	2	completed
NCT01789255	Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies	Cyclosporine Methotrexate Tacrolimus Vorinostat	supportive_care	2	completed
NCT00077155	Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma	Cilengitide	treatment	1	completed
NCT00112723	Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma	Alvocidib	treatment	1 / 2	terminated
NCT03288415	SMZL Molecular Prognostic Index	No drug interventions	Not Available	Not Available	active_not_recruiting